If you watch television, you've probably come across a commercial for AndroGel, AbbVie's (ABBV 0.25%) blockbuster prescription gel for treating low testosterone levels. The technical term for the ailment is hypogonadism, and it's a $2 billion market -- and growing. Markets like that don't come without admirers, and in this case one of those is Repros Therapeutics (NASDAQ: RPRX). The company is developing an oral drug for secondary hypogonadism called Androxal, and in the following video Brenton Flynn discusses why its stock soared today.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.